Polyglutamine-containing proteins expressed in the CAG repeat diseases Huntington's disease and dentatorubralpallidoluyisian atrophy have recently been suggested to inhibit the key glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH). To examine the consequences of GAPDH inhibition upon neuronal survival, we exposed murine neocortical cell cultures to the inhibitor of GAPDH and triosephosphate isomerase, ␣-monochlorohydrin. Cultures exposed to 6-15 mM ␣-monochlorohydrin for 48 h exhibited an increase in dihydroxyacetone phosphate and a decrease in neuronal ATP that was followed by progressive neuronal death; some glial death occurred at high drug concentrations. The neuronal death was characterized by cell body shrinkage and chromatin condensation and was sensitive to cycloheximide and to the caspase inhibitors Z-Val-Ala-Asp fluoromethylketone and tert-butoxycarbonyl-Asp fluoromethylketone. Neurons in striatal cell cultures were more vulnerable to death induced by exposure to ␣-monochlorohydrin, except that NADPHdiaphorase(؉) neurons were selectively spared. Repeated addition of the glycolytic endpoint metabolite pyruvate to the bathing medium attenuated both the drop in neuronal ATP and the neuronal cell death. 1998 Academic Press
INTRODUCTION
Huntington's disease (HD) is an autosomal dominant disease characterized by progressive chorea and dementia. The genetic defect in HD consists of an increase in the length of a CAG triplet repeat in a gene called ''huntingtin'' located on chromosome 4p16.3 (Huntington's Disease Collaborative Research Group, 1993) . Other trinucleotide repeat diseases have been identified, many of which also involve CAG repeats in coding sequences (Willems, 1994) .
It has recently been reported that polyglutamine peptides bind strongly to glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a key enzyme in glycolysis. Furthermore, when brain extract was passed over a GAPDH protein column, both huntingtin and dentatorubralpallidoluysian atrophy protein (atrophin-1) were retained on the column (Burke et al., 1996) . GAPDH has been shown to be a key control point for glycolysis with a control strength on glycolysis near 1 for nondividing bacterial cells (Poolman et al., 1987) . These data raise the interesting possibility that neuronal death in triplet repeat diseases may be triggered by GAPDH inhibition, leading to reduced glycolysis and consequent cellular energy shortages. Energy depletion has been postulated to contribute to neuronal cell death in several neurodegenerative diseases (Beal, 1992; Wallace, 1992; Beal et al., 1993) , and inhibitors of mitochondrial electron transport have been used to model the specific pattern of neuronal loss seen in HD (Beal et al., 1993; Behrens et al., 1995) .
To determine the consequences of GAPDH inhibition upon neuronal cell survival, we turned to ␣-monochlorohydrin, which is metabolized within cells to ␣-chlorolactaldehyde, a specific inhibitor of triosephosphate isomerase and GAPDH (Cooney & Jones, 1988 ). An abstract has appeared (Sheline & Choi, 1996) .
